Brooklands Fund Management Ltd Acquires New Position in Novo Nordisk A/S $NVO

Brooklands Fund Management Ltd acquired a new stake in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 35,470 shares of the company’s stock, valued at approximately $1,805,000. Novo Nordisk A/S accounts for 0.2% of Brooklands Fund Management Ltd’s portfolio, making the stock its 18th largest holding.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVO. Franklin Resources Inc. raised its stake in Novo Nordisk A/S by 4,190.8% in the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after acquiring an additional 13,658,867 shares during the period. Capital International Investors raised its stake in Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $310,199,000. Bank of Montreal Can raised its stake in Novo Nordisk A/S by 138.9% in the 4th quarter. Bank of Montreal Can now owns 2,525,827 shares of the company’s stock valued at $128,514,000 after acquiring an additional 1,468,409 shares during the period. Finally, Clear Street Group Inc. purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at about $56,378,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on NVO shares. Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a report on Tuesday, March 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Finally, Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $43.85 on Tuesday. The company has a market cap of $195.81 billion, a PE ratio of 10.29, a price-to-earnings-growth ratio of 3.92 and a beta of 0.78. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average price of $42.42 and a 200-day moving average price of $45.98. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $78.38.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.